Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

18.8%

24 terminated/withdrawn out of 128 trials

Success Rate

75.8%

-10.8% vs industry average

Late-Stage Pipeline

1%

1 trials in Phase 3/4

Results Transparency

75%

56 of 75 completed trials have results

Key Signals

14 recruiting56 with results18 terminated6 withdrawn

Enrollment Performance

Analytics

Phase 2
53(42.4%)
Phase 1
50(40.0%)
N/A
21(16.8%)
Phase 3
1(0.8%)
125Total
Phase 2(53)
Phase 1(50)
N/A(21)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (128)

Showing 20 of 128 trials
NCT06396598Not ApplicableCompleted

Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer

Role: collaborator

NCT06064149Not ApplicableActive Not Recruiting

The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study

Role: collaborator

NCT06202820Not ApplicableRecruiting

CV CARE: CardioVascular Care in PC Patients

Role: collaborator

NCT07146646Phase 2Recruiting

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

Role: collaborator

NCT05274048Phase 1Recruiting

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Role: collaborator

NCT03410043Phase 2Active Not Recruiting

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

Role: collaborator

NCT07814352Phase 1Recruiting

A Study of SX-682 in Combination With Proton Craniospinal Irradiation (pCSI) in People With Leptomeningeal Disease

Role: collaborator

NCT07781800Not ApplicableNot Yet Recruiting

Navigation Interventions for Patients With Breast Cancer and High-risk Social Determinants of Health

Role: collaborator

NCT06681077Not ApplicableRecruiting

A Community Health Education Intervention for Increasing Community-driven Actions to Reduce the Cancer Burden in Western New York

Role: collaborator

NCT07802834Phase 2Not Yet Recruiting

Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC

Role: collaborator

NCT05089370Phase 1Active Not Recruiting

Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma

Role: collaborator

NCT04374305Phase 2Recruiting

Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

Role: collaborator

NCT07549139Not ApplicableNot Yet Recruiting

Overcoming Racial Disparities in Screening Mammography

Role: collaborator

NCT03392246Phase 2Active Not Recruiting

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Role: collaborator

NCT06483100Phase 2Recruiting

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

Role: collaborator

NCT05832008Not ApplicableCompleted

Increasing Adherence to Lung Cancer Screening

Role: collaborator

NCT06109467Phase 2Active Not Recruiting

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Role: collaborator

NCT03786692Phase 2Active Not Recruiting

Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

Role: collaborator

NCT01885949Phase 2Terminated

Tivozanib + Enzalutamide in Adv Prostate Cancer

Role: collaborator

NCT01840592Phase 2Active Not Recruiting

Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib

Role: collaborator